Loading...
Insights2021-01-12T11:48:07-05:00

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Executive Summary: State of the Industry

Cell & Gene Therapy, News, Thought Leadership|

Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), kicked off the event with a briefing on the state of the cell and gene therapy development landscape. With 475 members worldwide, ARM focuses on convening the sector, providing data and analysis, engaging with stakeholders, and enabling the development of advanced therapies. One of their key initiatives is modernizing healthcare systems to enable access to these novel therapeutics. Highlights of this briefing are provided in this summary.

(more…)

Article: Innovations in Gene Therapies

Cell & Gene Therapy|

Despite innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought into focus the need for even more advancement in the field. In this Pharma Live article, Precision’s Phil Cyr discusses some of the innovations that are occurring to address these issues.

(more…)

Webinar: Driving Successful Therapeutic and Diagnostic Development: Effective Practices for Integrating Biomarkers, Biospecimens, and Science from Concept through Clinic to Cloud

Events|

In the rapidly evolving world of precision medicine, the successful integration of high-quality biospecimens and well-defined biomarkers is a fundamental aspect. Together with robust scientific methodologies and validation procedures, they drive discovery, clinical development, and the advent of Artificial Intelligence (AI)-driven diagnostics.

This webinar delves into the practical application of biospecimens in critical areas like neurodegeneration, immuno-oncology, and oncology. It outlines the development of assays for clinical application, the creation of multiplexed Immunohistochemistry (IHC) assays, and the use of sequenced biospecimens in the development and diagnosis of targeted therapies.

Key topics will also highlight the value of Tissue Microarrays (TMAs), the advantage of accessing diverse disease indications, the necessity for substantial tissue cohorts for clinical trial assay validation, and the role of tissue images (Hematoxylin & Eosin (H&E), IHC) and related sample data (Next-Generation Sequencing (NGS)) in shaping AI-based diagnostics.

(more…)

White Paper: Gene Editing Breakthroughs: A New Hope for Patients

Cell & Gene Therapy, News, Thought Leadership|

Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.

In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.

(more…)

Load More Posts